Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Dose-Escalation Study Evaluating Pharmacokinetics and Safety of Anthrax Immune Globulin Intravenous (AIGIV)

NCT00845650 is registered in ClinicalTrials.gov with Emergent BioSolutions as lead sponsor.

NCT NCT00845650
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00845650 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Dose-Escalation Study Evaluating Pharmacokinetics and Safety of Anthrax Immune Globulin Intravenous (AIGIV)
Lead sponsor
Emergent BioSolutions
Phase
Phase 1/2
Overall status
Completed
Start date
February 28, 2009
Completion date
October 31, 2010
Enrollment
129 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anthrax